On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation Review uri icon

Overview

MeSH Major

  • Immune Tolerance
  • Lymphocyte Activation
  • Neoplasms
  • T-Lymphocytes

abstract

  • The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1126/scitranslmed.3010274

PubMed ID

  • 25810313

Additional Document Info

start page

  • 280sr1

volume

  • 7

number

  • 280